Chronic Ischemic cardiopathy

Estenosis aórtica: prevalencia, directrices, nuevos tratamientos y datos actuales.

solaci
solaci
253
0

Estudios epidemiológicos han determinado que una de cada ocho personas de 75 años o mayores sufren de estenosis aórtica (EA) moderada o severa.1 Varios sondeos han mostrado que muchos pacientes con EA severa no se derivan a un equipo cardiológico para evaluar una sustitución de la válvula.2 La sustitución de válvula aórtica (SVA) quirúrgica es el criterio de referencia para el tratamiento de la EA severa y la implantación de la válvula aórtica transcatéter (TAVI) ofrece una nueva opción de tratamiento para aquellos pacientes considerados de alto riesgo para la cirugía.

http://solaci.org/es/pdfs/estenosis_medicos.pdf
SOLACI.ORG

Previous article
Tres Reglas para Identificar Infarto en la Guardia
Next article
Jornadas Paraguay 2011
solaci
solaci

More articles by this author

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Dr. Juan Manuel Pérez - 0
Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

Dr. Omar Tupayachi - 0
The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Dr. Omar Tupayachi - 0
Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

Dr. Omar Tupayachi - 0
After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Chronic Ischemic cardiopathy

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary...
Dr. Juan Manuel Pérez -
SOLACI Sessionsspot_img

Recent Articles

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Dr. Juan Manuel Pérez - 0
Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Dr. Juan Manuel Pérez - 0
Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Dr. Andrés Rodríguez - 0
Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...